967 related articles for article (PubMed ID: 31339232)
1. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
[TBL] [Abstract][Full Text] [Related]
2. Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF.
Anand IS; Konstam MA; Klein HU; Mann DL; Ardell JL; Gregory DD; Massaro JM; Libbus I; DiCarlo LA; Udelson JJE; Butler J; Parker JD; Teerlink JR
ESC Heart Fail; 2020 Feb; 7(1):75-83. PubMed ID: 31984682
[TBL] [Abstract][Full Text] [Related]
3. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Nguyen E; Weeda ER; White CM
J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
[TBL] [Abstract][Full Text] [Related]
4. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
Bhagat AA; Greene SJ; Vaduganathan M; Fonarow GC; Butler J
JACC Heart Fail; 2019 Jan; 7(1):1-12. PubMed ID: 30414818
[TBL] [Abstract][Full Text] [Related]
5. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
6. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
7. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
9. Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF).
Savarese G; Kishi T; Vardeny O; Adamsson Eryd S; Bodegård J; Lund LH; Thuresson M; Bozkurt B
JACC Heart Fail; 2023 Jan; 11(1):1-14. PubMed ID: 36202739
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz M; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2014 Jul; 16(7):817-25. PubMed ID: 24828035
[TBL] [Abstract][Full Text] [Related]
11. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
12. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
[TBL] [Abstract][Full Text] [Related]
13. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
[TBL] [Abstract][Full Text] [Related]
14. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
[TBL] [Abstract][Full Text] [Related]
15. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
[TBL] [Abstract][Full Text] [Related]
16. Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program.
Pokharel Y; Wei J; Hira RS; Kalra A; Shore S; Kerkar PG; Kumar G; Risch S; Vicera V; Oetgen WJ; Deswal A; Turakhia MP; Glusenkamp N; Virani SS
Clin Cardiol; 2016 Mar; 39(3):145-9. PubMed ID: 26880649
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological therapy of heart failure with reduced ejection fraction].
Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
[TBL] [Abstract][Full Text] [Related]
19. New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
Patel S; Veltri K
J Pharm Pract; 2017 Oct; 30(5):541-548. PubMed ID: 27194070
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
